News

The Cystic Fibrosis Foundation is investing up to $15 million in Recode Therapeutics to help spur the development of new gene-editing medicines for people with cystic fibrosis (CF) who don’t have effective treatment options. “We are grateful to the CF Foundation for their ongoing support of our…

A Phase 1/2 clinical trial testing the inhaled gene therapy SP-101 in adults with cystic fibrosis (CF) has begun dosing, and is still recruiting participants, according to its developer Spirovant Sciences. The trial, called SAAVe (NCT06526923), aims to enroll 15 CF patients, ages 18 to 65. To…

Rostra Therapeutics has launched a research project with the support of funding from the Cystic Fibrosis Antimicrobial Resistance (CF AMR) Syndicate that seeks to identify new small molecules that can destroy fungi or stop them from growing and causing infections in people with cystic fibrosis (CF). Rostra…

Researchers have created a new technology to measure the thickness of mucus in the airways, which could aid in monitoring for cystic fibrosis (CF) and other diseases that affect the lungs. The team, led by scientists at Vanderbilt University in Tennessee, described the technology in the study, “…

A more rapid decline in lung function in people with cystic fibrosis (CF) has been linked in a new study to high sputum levels of a virus that infects the bacteria Pseudomonas aeruginosa, which is a major contributor to lung disease in CF. The virus, called Pseudomonas filamentous…

Airway epithelial cells carrying mutations that cause cystic fibrosis (CF) become more loosely connected when grown in the lab in the presence of insulin and high amounts of sugar, a study found, suggesting that CF-related diabetes may weaken the barrier that normally protects the airway tract. Researchers working at…

Bonnie Ramsey, MD, a pediatrician and researcher who dedicated her career to advancing care for cystic fibrosis (CF), has been selected as the recipient of the 2025 American Pediatric Society (APS) John Howland Award. The APS has been giving this award since the early 1950s to recognize healthcare workers…

A Phase 1 trial that’s evaluating the safety and tolerability of an inhaled treatment called KIT2014 in healthy volunteers has started in Australia. KIT2014 is being developed by Kither Biotech as an add-on to existing CTFR modulators, to improve lung function and reduce inflammation in cystic fibrosis (CF)…

The cystic fibrosis (CF) treatment Trikafta leads to changes in airway cell gene expression, or activity, that may help fend off bacterial infections and lessen lung damage, researchers report. “This study identifies mechanisms through which ETI [Trikafta] is likely to improve antibacterial function, reduce lung damage, and reduce…

Treatment with Trikafta triggered diabetes remission in four people with cystic fibrosis (CF) at a center in Australia, with each of these patients experiencing complete resolution of CF-related diabetes, or CFRD, after starting on the approved triple therapy. In all four cases, the patients were able to stop…